Your browser is no longer supported. Please, upgrade your browser.
Settings
ABT Abbott Laboratories daily Stock Chart
ABT [NYSE]
Abbott Laboratories
IndexS&P 500 P/E37.15 EPS (ttm)1.33 Insider Own0.30% Shs Outstand1.49B Perf Week0.16%
Market Cap73.56B Forward P/E20.53 EPS next Y2.41 Insider Trans-3.73% Shs Float1.49B Perf Month1.13%
Income2.03B PEG3.83 EPS next Q0.50 Inst Own70.20% Short Float0.84% Perf Quarter7.66%
Sales20.39B P/S3.61 EPS this Y-10.30% Inst Trans-1.31% Short Ratio2.73 Perf Half Y10.90%
Book/sh14.53 P/B3.40 EPS next Y11.38% ROA10.90% Target Price51.41 Perf Year20.75%
Cash/sh6.62 P/C7.47 EPS next 5Y9.70% ROE20.40% 52W Range38.87 - 50.47 Perf YTD10.90%
Dividend0.96 P/FCF79.87 EPS past 5Y-21.10% ROI6.20% 52W High-2.10% Beta0.65
Dividend %1.94% Quick Ratio1.90 Sales past 5Y-8.00% Gross Margin55.80% 52W Low27.10% ATR0.66
Employees77000 Current Ratio2.20 Sales Q/Q3.00% Oper. Margin14.80% RSI (14)55.36 Volatility1.41% 1.26%
OptionableYes Debt/Eq0.39 EPS Q/Q150.00% Profit Margin22.40% Rel Volume0.60 Prev Close49.52
ShortableYes LT Debt/Eq0.27 EarningsJul 15 BMO Payout30.30% Avg Volume4.58M Price49.41
Recom2.00 SMA200.71% SMA501.98% SMA2008.85% Volume2,740,289 Change-0.22%
Apr-23-15Reiterated Stifel Buy $52 → $53
Mar-27-15Reiterated Barclays Equal Weight $48 → $52
Jan-30-15Reiterated Stifel Buy $47 → $49
Jan-30-15Reiterated Barclays Equal Weight $43 → $48
Sep-22-14Reiterated RBC Capital Mkts Outperform $44 → $48
Jul-17-14Reiterated Stifel Buy $42 → $47
Jul-17-14Reiterated Barclays Equal Weight $40 → $43
Mar-10-14Initiated Singular Research Sell $30
Dec-16-13Reiterated Deutsche Bank Hold $37 → $39
Oct-07-13Reiterated Stifel Buy $44 → $40
Jul-18-13Reiterated Barclays Equal Weight $35 → $37
May-28-13Reiterated RBC Capital Mkts Outperform $38 → $42
May-21-13Initiated Gabelli & Co Buy
Apr-19-13Reiterated RBC Capital Mkts Outperform $37 → $38
Apr-18-13Reiterated Stifel Buy $40 → $44
Apr-12-13Reiterated Deutsche Bank Hold $33 → $35
Feb-15-13Initiated Stifel Nicolaus Buy $40
Jan-11-13Reiterated UBS Buy $75 → $38
Jan-11-13Initiated Barclays Equal Weight $35
Jan-04-13Downgrade Deutsche Bank Buy → Hold $70 → $33
Jul-01-15 02:24PM  These stocks win in 2nd half
09:00AM  Abbott Hosts Conference Call for Second-Quarter Earnings PR Newswire
Jun-30-15 02:35PM  Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog
09:10AM  Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog
Jun-29-15 04:45PM  Novartis' Cosentyx Positive in Psoriatic Arthritis Study - Analyst Blog
12:00PM  Activist investors love spin-offs. Heres why you should, too at Fortune
12:21AM  Easier Blood-Sugar Monitoring for Diabetics at The Wall Street Journal
Jun-28-15 09:49AM  5 Trade Ideas for Monday: Abbott Labs, Cognex, Lazard, Northern Trust & Tractor Supply
Jun-26-15 07:48AM  The 5 stocks to buy with rising rates: Portfolio manager
Jun-22-15 08:30AM  3 Healthcare Stocks For A Growing Global Middle Class
Jun-17-15 04:50PM  Mylan Inks Deal with Pulmatrix for Respiratory Disease Drug - Analyst Blog
Jun-16-15 08:01PM  Abbott Backs Mylan and Its Strategy to Buy Perrigo at TheStreet
05:43PM  Big shareholder backs drugmaker Mylan's growth strategy
05:06PM  Stocks End Near Highs; Perrigo Rebounds On Mylan Deal at Investor's Business Daily
04:33PM  Aetna and Coty are big market movers
04:12PM  Deal talk drives US stocks to modest gains
03:20PM  US stocks gain; Coty surges on P&G beauty deal reports
12:12PM  How An Inversion Is Paying Off Twice In Mylan's Fight Against Teva Pharmaceutical at Forbes
11:25AM  Mylan's largest shareholder Abbott Laboratories backs in Perrigo bid at bizjournals.com
10:11AM  Abbott to Vote in Favor of Mylan's Perrigo Deal at The Wall Street Journal
09:20AM  Abbott to vote for Mylan's acquisition of Perrigo
09:19AM  Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction PR Newswire
09:17AM  Abbott Will Back Mylans Perrigo Bid Using 14.5% Share Stake at Bloomberg
09:00AM  Abbott Affirms its Support for Mylan Standalone Strategy and Will Vote its Mylan Shares in Favor of Mylan's Proposed Acquisition of Perrigo PR Newswire
Jun-12-15 10:28AM  Abbott Declares 366th Consecutive Quarterly Dividend PR Newswire
Jun-09-15 02:11PM  These companies have made every Fortune 500 list for 61 years at Fortune
Jun-08-15 10:30AM  Dont Forget This Healthcare ETF
Jun-05-15 03:59PM  Abbott & Costello heirs sue over 'Who's on First?' at CNBC
Jun-04-15 02:17PM  Horizon Pharma Survives Through Transformation at Investor's Business Daily
Jun-02-15 09:30AM  Medical Devices ETFs to Capture Emerging Market Growth
Jun-01-15 01:38PM  Get the most bang for the buck
10:09AM  Biotech isn't only health care bet beating market at CNBC
09:38AM  UBS Reviews ASCO, Notes Weekend Data Points From 2 Companies
May-28-15 06:00PM  Making Money With Charles Payne: 05/28/15 at Fox Business
03:11PM  Pfizer: Split Decision Could Come Earlier Than You Think at Barrons.com
May-27-15 02:06PM  The real issue with Greece
May-20-15 10:40AM  China Diabetes Management Devices Market Growth to be Driven by Rise in Sedentary Lifestyle and Life Expectancy and Patient Compliant Technologies Especially for Insulin Pump and CGM PR Newswire
08:17AM  Out with the old, in with the new stock swaps
May-19-15 08:00AM  Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease PR Newswire
May-18-15 08:48PM  Credits & Debits: News Digest at The Wall Street Journal
08:12PM  [$$] Credits & Debits: News Digest at The Wall Street Journal
07:24PM  A third of Pedialyte's sales now comes from adults at CNBC
10:46AM  Tech firm raises $1.5m from crowd sourcing AAP
10:06AM  Tech firm raises $1.5m from crowdsourcing AAP
May-15-15 04:21PM  Healthcare Winners and Losers: May 15, 2015
May-14-15 08:59AM  How a drink for babies became the adult hangover cure of choice at MarketWatch
08:59AM  How a drink for babies became the adult hangover cure of choice
12:39AM  Pedialyte Sales GrowInto an Adult Market at The Wall Street Journal
May-13-15 07:44PM  Pedialyte Sales Grow---Into an Adult Market at The Wall Street Journal
01:04PM  ABBOTT LABORATORIES Financials
May-12-15 07:01PM  AstraZeneca digs into precision medicine with lung, heart deals
07:34AM  Small business the budget centrepiece AAP
05:41AM  Easier set up for start-ups AAP
May-11-15 06:02PM  CFO Moves: Abbott Laboratories, Synaptics, Enstar at The Wall Street Journal
10:25AM  ABBOTT LABORATORIES Files SEC form 8-K, Change in Directors or Principal Officers
May-08-15 08:09PM  10-Q for Abbott Laboratories at Company Spotlight
03:33PM  Mylan Reports 1Q15 Earnings Per Share Growth of 6%
May-07-15 05:55PM  Abbotts Mylan Billions Open Door for Bigger Purchases: Real M&A at Bloomberg
05:39PM  Jim Chanos, Kyle Bass Rip Oil And Pharma At SALT 2015
May-06-15 05:02PM  ABBOTT LABORATORIES Files SEC form 10-Q, Quarterly Report
05:53AM  Zoetis (ZTS) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
04:58AM  Mylan (MYL) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
May-05-15 03:25PM  New CEO takes over evolving drugmaker Bristol-Myers Squibb
04:24AM  India Coronary Stent Market to be Tripled by 2021 PR Newswire
May-04-15 04:00PM  Can Mylan (MYL) Specialty Segment Secure Earnings Beat? - Analyst Blog
Apr-30-15 09:00AM  Abbott's First-of-its-Kind Blood Test to Aid in Detecting Early Pregnancy Could Help Doctors Make Faster Treatment Decisions for Women PR Newswire
Apr-27-15 08:24PM  Congress Pressed on Baby-Formula Vouchers at The Wall Street Journal
05:20PM  ABBOTT LABORATORIES Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
03:39PM  Teva Said to Take Acquisition Bid Directly to Mylan Holders at Bloomberg
11:26AM  Akorn Downgraded, Stock Falls On 'Credibility Gap' at Investor's Business Daily
Apr-24-15 04:42PM  Abbott Laboratories (ABT) Earnings Analysis: By the Numbers
11:16AM  Heres what CEOs said about the economy this week
03:32AM  AbbVie (ABBV) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
Apr-23-15 04:16PM  DepoMed Set To Grow On 'Transformative' Nucynta Deal at Investor's Business Daily
03:55PM  Dealpolitik: Three Ways to Look at the Three-Way Pharma Scrum at The Wall Street Journal
12:06PM  Earnings for US Multinationals Beat Estimates Despite Currency War
10:45AM  Abbvie's CEO Gonzalez: We're Now In Pharma's 'Top Tier' at Forbes
10:10AM  Company News for April 23, 2015 - Corporate Summary
Apr-22-15 08:17PM  Mylan readies its poison pill defences at Financial Times
04:55PM  Abbott Laboratories (ABT) Stock Gained Today on Strong Earnings Beat at TheStreet
02:07PM  Abbott posts profit beat
01:41PM  Earnings Beat Propels Abbott Laboratories To New All-Time High
01:18PM  Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
01:00PM  Mylan Deal Is Abbotts Gain as Drugmakers Stake Grows and Grows at Bloomberg
12:53PM  Abbott Laboratories (ABT) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
12:09PM  Abbott says its payoff from Mylan deal surged
12:06PM  Abbott says payoff from Mylan deal surges, as Mylan shares leap
10:54AM  St. Jude, Abbott Labs Beat Q1 Expectations at Investor's Business Daily
09:22AM  Abbott Labs (ABT) Beats On Earnings in Q1 - Tale of the Tape
09:16AM  Abbott Labs Reports Better-Than-Expected Profit at The Wall Street Journal
09:09AM  Abbott profit beats expectations, sales of branded generics jump
09:04AM  Abbott Profit Beats Estimates as Emerging Market Sales Rise
09:00AM  Abbott Laboratories Earnings Call scheduled for 9:00 am ET today
08:18AM  A Vulnerable Market, Oil Price And Chart Resistance at Investor's Business Daily
08:08AM  ABBOTT LABORATORIES Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
08:05AM  Abbott Labs profit from continuing operations more than doubles
07:57AM  Abbott beats Street 1Q forecasts
07:55AM  Abbott Labs Profit Beats Estimates as Emerging Market Sales Rise at Bloomberg
07:45AM  Abbott Reports First-Quarter 2015 Results PR Newswire
07:07AM  Q1 2015 Abbott Laboratories Earnings Release - Before Market Open
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon. The company's Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as prepared infant and follow-on formula. The company's Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices to treat vascular diseases. Abbott Laboratories also offers blood, continuous, and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes under the FreeStyle brand; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices, and government agencies. It has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pavee Jean-YvesSenior Vice PresidentJun 03Option Exercise25.9810,500272,77536,106Jun 05 06:05 PM
Pavee Jean-YvesSenior Vice PresidentJun 03Sale49.0010,500514,50025,606Jun 05 06:05 PM
BIRD ROGERSenior Vice PresidentApr 27Option Exercise23.0124,348560,22366,358Apr 29 06:23 PM
Mason Heather LExecutive Vice PresidentApr 27Sale47.4513,500640,599121,489Apr 29 06:24 PM
BIRD ROGERSenior Vice PresidentApr 27Sale47.5728,5481,357,88937,810Apr 29 06:23 PM
Contreras JaimeSenior Vice PresidentMar 31Sale46.4322810,5862,094Apr 02 05:03 PM
White J. ScottSenior Vice PresidentMar 26Option Exercise22.4918,600418,364108,202Mar 27 05:10 PM
White J. ScottSenior Vice PresidentMar 26Sale46.6812,483582,66395,719Mar 27 05:10 PM
Warmuth Michael JExecutive Vice PresidentMar 10Sale46.4113,500626,58149,433Mar 12 05:32 PM
Contreras JaimeSenior Vice PresidentMar 02Sale47.349,209435,95436,898Mar 03 05:20 PM
Pavee Jean-YvesSenior Vice PresidentMar 02Sale47.4865230,95825,606Mar 03 05:07 PM
Contreras JaimeSenior Vice PresidentFeb 18Sale46.2642319,5681,379Feb 18 05:49 PM
Simhambhatla Murthy VSenior Vice PresidentFeb 17Sale46.411727,98345,199Feb 19 05:11 PM
ALLEN HUBERT LExecutive Vice PresidentFeb 17Sale46.381727,97851,941Feb 19 05:12 PM
Pavee Jean-YvesSenior Vice PresidentFeb 17Sale46.4162128,82122,912Feb 18 06:45 PM
Funck Robert EVice President, ControllerFeb 13Option Exercise22.2710,542234,73973,468Feb 17 05:55 PM
CAPEK JOHN MExecutive Vice PresidentFeb 04Option Exercise25.2583,0002,095,426309,945Feb 06 05:11 PM
CAPEK JOHN MExecutive Vice PresidentFeb 04Sale45.7638,7731,774,430236,880Feb 06 05:11 PM
CAPEK JOHN MExecutive Vice PresidentFeb 04Sale45.839,935455,340226,945Feb 06 05:12 PM
CAPEK JOHN MExecutive Vice PresidentFeb 04Sale45.6634,2921,565,612275,653Feb 06 05:11 PM
Contreras JaimeSenior Vice PresidentNov 25Option Exercise26.4651,6001,365,50481,736Nov 26 05:06 PM
Contreras JaimeSenior Vice PresidentNov 25Sale44.0751,6002,274,08030,136Nov 26 05:06 PM
WHITE MILES DChairman and CEOOct 29Option Exercise22.2738,034846,9031,452,559Oct 30 06:04 PM
WHITE MILES DChairman and CEOOct 29Sale42.7038,0341,624,0521,414,525Oct 30 06:04 PM
WHITE MILES DChairman and CEOOct 28Option Exercise22.27402,7668,968,3911,817,291Oct 30 06:04 PM
WHITE MILES DChairman and CEOOct 28Sale42.50402,76617,117,6341,414,525Oct 30 06:04 PM
Fussell Stephen RExecutive Vice PresidentSep 18Option Exercise22.7931,900726,872141,664Sep 19 05:10 PM
FREYMAN THOMAS CExecutive Vice PresidentJul 21Option Exercise24.0779,0001,901,828390,326Jul 22 05:03 PM